TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients less than 12 months of age who have been admitted to the hospital after brief resolved unexplained event~Exclusion Criteria:~* Patients with any pre-existing significant medical diagnosis (congenital heart disease, known neurologic impairment with or without seizure disorder, other congenital anomalies)~* Patients with any prior hospitalization for BRUE~* Patients with food allergies such that they cannot be on a milk or rice based diet~* Any patient exclusively breastfed because change to a formula or adding thickening is not possible unless patients choose to pump breast milk and stop all nursing

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 1 Year
- Healthy Volunteers: f

Study Arms:
- Standard Formula (Type: NO_INTERVENTION): This is the group of subjects randomized to receive their standard formula
- Standard Formula with Rice Cereal (Type: EXPERIMENTAL): This is the group of subjects randomized to receive their standard formula with rice cereal added
- Enfamil AR (Type: EXPERIMENTAL): This is the group of subjects randomized to receive Enfamil AR

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with histologically confirmed diagnosis of primary solid tumor, and with pathologically or radiologically documented metastases~* Disease that is measurable or evaluable by RECIST 1.1 criteria (for Solid Tumors)~* Patient with metastatic cancer that are refractory to current standard/available therapies~Exclusion Criteria:~* brain metastases~* serious concurrent infection or nonmalignant illness that is uncontrolled~* uncontrolled intercurrent illness~* Immunocompromised~* significant traumatic injury within 3 weeks before Day 0~* History of hypersensitivity to any component of study drug

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 188Re-BMEDA-liposome (Type: EXPERIMENTAL): Stage I:~188Re-BMEDA-liposomes, 14±1.4 mCi, single dose~Stage II:~188Re-BMEDA-liposomes, dose-escalation, single dose Dose Level Dose of 188Re-BMEDA-liposome (mCi/kg)~1. 0.42±0.04 mCi/kg~2. 0.63±0.06 mCi/kg~3. 0.84±0.08 mCi/kg~4. 1.05±0.11 mCi/kg~5. 1.26±0.13 mCi/kg~6. 1.47±0.15 mCi/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Viral and Host Factors in the Transmission and Pathogenesis of HIV

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~recently infected with HIV-1 HIV-1 negative, and at high risk for infection~Exclusion Criteria:~none

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- high risk (Type: None): Blood draw from individuals known to be or at high risk for HIV-infection
- diagnosed (Type: None): Blood draw f rom individuals diagnosed with HIV infection

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Infant Flow Biphasic Nasal Continuous Airway Pressure (NCPAP) Versus Infant Flow NCPAP for the Facilitation of Extubation in Infants </= 1250 Grams

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants \</= 1250 grams who are going to be extubated~Exclusion Criteria:~* Congenital abnormalities of the upper airway~* Acquired nasal septum injury~* Congenital Heart Disease excluding Patent Ductus arteriosus

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Biphasic NCPAP
- 2 (Type: ACTIVE_COMPARATOR): Continuous CPAP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed newly diagnosed benign intracranial meningioma~  * WHO grade I~ * Any location except orbital meningioma~* Mitotic index \< 4 (total counts per 10 high-power field) AND MIB-1 labeling index \< 4%~* The following histologies are not allowed (i.e., WHO grade II or III):~  * Atypical~ * Clear cell~ * Choroid~ * Rhabdoid~ * Papillary~ * Anaplastic~* Must have undergone non-radical resection\* within the past 7 months~  * Post-operative MRI (performed 4 months after surgery) demonstrating stages 3, 4, or 5 NOTE: \*Biopsy only is considered non-radical resection and may be classified as stage 4 or 5 according to tumor volume~* No brain invasion~* No hemangiopericytoma~* No fibrous dysplasia or intra-osseous meningioma~* No multiple meningiomas or meningiomatosis~* Not part of neurofibromatosis type II~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* WHO 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Not specified~Renal~* Not specified~Cardiovascular~* No serious congestive heart failure~Other~* HIV negative~* No other malignancy except basal cell skin cancer or carcinoma in situ of the cervix~* No other disease that would preclude 5-year follow up after study completion~* No psychological, familial, sociological, or geographical condition that would preclude study compliance or study follow up~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* Not specified~Endocrine therapy~* Not specified~Radiotherapy~* No prior radiotherapy to the meninges or brain that would preclude study treatment~Surgery~* See Disease Characteristics~Other~* No prior randomization to this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~CASES are those who:~* Survived at least 100 days post-hematopoietic stem cell transplantation (HSCT).~* Developed an SMN after that time point.~* And received TBI as part of the preparative regimen.~CONTROLS are randomly selected:~* In a 4:1 ratio to cases from the same cohort of 100 day + survivors of HSCT who received TBI.~* Controls will be matched to the cases by race and primary diagnosis.~* In addition, they must have survived for at least the elapsed time between the case's HSCT and the secondary cancer, without development of an SMN.~* We are matching on primary diagnosis, as genotype or radiation sensitivity may predispose to specific primary cancers, as well as the SMNs.~* We are matching on race, as allele frequencies vary widely across ethnic groups.~Exclusion Criteria:~* Did not survive at least 100 days post-hematopoietic stem cell transplantation (HSCT).~* Did not develop an SMN after that time point.~* Did not receive TBI as part of the preparative regimen.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Osteopathic Treatment on Pulmonary Function After Coronary Artery Bypass Graft Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Planned Coronary Artery Bypass Graft (CABG) surgery at the Jessa Hospital Hasselt~* Planned Endoscopic Atraumatic Coronary Artery Bypass (endo ACAB) surgery at the Jessa Hospital~* Planned Minimal Invasive Aortic Valve Replacement (mini AVR) surgery at the Jessa Hospital~Exclusion Criteria:~* Thoracic surgery in the past~* Redo CABG~* Complications after CABG, requiring long-term (more than 6 days) admission to intensive care~* Pathologies of the lungs~* Pathologies of the heart, other than the coronary artery disease~* Surgery in the sub diaphragmatic region: epigastric region, left and right hypochondriac region.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care (Type: ACTIVE_COMPARATOR): Patients following the outpatient cardiac rehabilitation program.
- Usual care and Osteopathic treatment (Type: EXPERIMENTAL): Patients following the outpatient cardiac rehabilitation program and receiving osteopathic treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must have had a heart transplant.~* Patients must be less than 16 years of age.~Exclusion Criteria:~* Patients who have not had a heart transplant.~* Patients who are greater than 16 years of age.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has provided written informed consent with Health Information Portability and Accountability Act (HIPAA) authorization before the initiation of any study-related procedures.~* Subjects must be ≥18 years old;~* The subject must have a diagnosis of adenocarcinoma of the colon and/or rectum with FDG PET/CT confirmed metastases to the liver;~* The subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-3;~* The subject must be at least 4 weeks past any major intraabdominal surgery, including surgery to the liver;~* Subjects with prior malignancies other than colon and/or rectum cancer are allowed, provided they have been treated with curative intent, and have no evidence of recurrence of that malignancy;~* Each subject must have no more than 10 qualifying liver lesions that have been clinically confirmed metastatic adenocarcinoma of the colon by FDG PET/CT imaging.~* If of childbearing potential, the subject has a negative urine pregnancy test within 48 hours before administration of Tc 99m Tilmanocept, has been surgically sterilized, or has been postmenopausal for at least 1 year~Exclusion Criteria:~* The subject is pregnant or lactating.~* The subject has undergone any liver surgery, exclusive of a biopsy.~* The subject has known sensitivity to dextran.~* The subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 10 days prior to Tc 99m Tilmanocept administration~* Before the administration of Tc 99m Tilmanocept, has received any radiopharmaceutical within 7 radioactive half-lives of that radiopharmaceutical~* Has received an investigational product within the 30 days prior to Tc 99m Tilmanocept administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Subjects will receive 50 µg tilmanocept radiolabeled with 2.0 millicuries (mCi) Tc99m through a single IV injection.
- Cohort 2 (Type: EXPERIMENTAL): Subjects will receive 200 µg tilmanocept radiolabeled with 2.0 mCi Tc99m through a single IV injection.~If it was determined that additional enrollment would not provide meaningful data, for example no metastatic liver lesions were visualized by Tc 99m tilmanocept for any of the subjects in the cohort, enrollment into Cohort 2 would begin and 3 subjects would be enrolled followed by a review of the imaging and safety data.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Imatinib Mesylate With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed or Recurrent Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Age 3 to 21~* Performance status of Karnofsky 50-100% OR Lansky 50-100%~* Absolute neutrophil count greater than 1,000/mm3~* Platelet count greater than 100,000/mm3 (transfusion independent)~* Hemoglobin greater than 8 g/dL (transfusion allowed)~* Bilirubin no greater than 1.5 times normal for age~* SGPT less than 3 times normal for age~* Albumin at least 2 g/dL~* Creatinine less than 1.5 times normal for age OR Glomerular filtration rate greater than 70 mL/min~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception during and for 6 months after study participation~* Stratum I~  * Newly diagnosed diffuse intrinsic brainstem malignant glioma~ * No disseminated disease~ * No radiographic evidence of intratumoral hemorrhage before or during radiotherapy~ * No prior chemotherapy (beyond routine corticosteroids)~ * No prior irradiation~ * Must not be receiving enzyme-inducing anticonvulsant drugs~* Stratum II~  * Histologically confirmed recurrent or refractory anaplastic astrocytoma, glioblastoma multiforme, or other high-grade glioma (including recurrent brain stem glioma~ * No intratumoral hemorrhage unrelated to prior surgical procedure~ * No myelosuppressive chemotherapy within 3 weeks (6 weeks if a nitrosourea agent) of study entry~ * No prior imatinib mesylate~ * At least 3 months since prior craniospinal radiotherapy (18 Gy or more)~ * At least 8 weeks since prior local radiotherapy to primary tumor~ * At least 2 weeks since prior focal radiotherapy for symptomatic~ * At least 3 months since prior bone marrow transplantation~ * Neurological deficits allowed if stable for at least 1 week prior to study~Exclusion Criteria~* Receiving other anticancer or experimental drug therapy.~* Ongoing uncontrolled infection.~* Significant cardiac, hepatic, gastrointestinal, renal, pulmonary, or psychiatric disease.~* Deep venous or arterial thrombosis within 6 weeks of registration.~* Taking warfarin.~* Newly diagnosed diffuse intrinsic brainstem malignant glioma with disseminated disease (stratum I)~* Intratumoral hemorrhage

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Enhanced Recovery Protocol After Minimally Invasive Lumbar Surgery.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult male or female (18 years or older)~* Patient who has agreed to participate in the study and has read and signed the consent form for participation in the study~* Patient for whom a minimally invasive spine surgery is planned: (dicectomy, lumbar canal recalibration with or without laminectomy, lumbar arthrodesis by posterior approach limited to one stage)~Exclusion Criteria:~* Patient with a contraindication to spinal anaesthesia~* A bedridden or institutionalised patient~* Mental deficiency or any other reason that may hinder the understanding or the strict application of the protocol~* Patient not affiliated to the French social security system~* Patient under legal protection, guardianship or curatorship~* Patient already included in another therapeutic study protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- Minimally invasive surgery of the lumbar spine with ERAS (Type: None): Minimally invasive surgery of the lumbar spine with Enhanced Recovery After Surgery (ERAS)
- Minimally invasive surgery of the lumbar spine (Type: None): Minimally invasive surgery of the lumbar spine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Mitomycin-C Application in Laryngotracheal Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with laryngotracheal stenosis, including subglottic stenosis or tracheal stenosis~* Patients with disease amenable to treatment with endoscopic CO2 laser radial incisions and balloon dilation~* Age greater than or equal to 18 years~Exclusion Criteria:~* Age less than 18 years~* Pregnancy~* Patients with glottic and supraglottic stenosis~* Patients with disease not amenable to treatment with endoscopic CO2 laser radial incisions and balloon dilation~* Patients with cartilaginous subglottic or tracheal stenosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mitomycin-C (Type: EXPERIMENTAL): Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of MMC in the radial incisions.
- Saline (Type: PLACEBO_COMPARATOR): Patients will undergo standard endoscopic surgical treatment for LTS involving CO2 laser radial incisions and balloon dilation, as well as topical application of isotonic saline in the radial incisions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologic confirmation of NSCLC.~* Patients have measurable or evaluable lesions based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria.~  * Unresectable phase IIIA(N2) and IIIB lung cancer confirmed by PET/CT, CT or MRI.~ * Whole lung V20\>=35% when giving 60Gy which is the minimum dose of radical irradiation.~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.~* Previously treated with chemotherapy or treatment-naive~* No previous chest radiotherapy, immunotherapy or biotherapy~* Hemoglobin≥10 mg/dL, platelet≥100000/μL,absolute neutrophil count ≥1500/μL~* Serum creatinine ≤1.25 times the upper normal limit(UNL), or creatinine clearance≥60 ml/min~* Bilirubin ≤1.5 times UNL, AST（SGOT）≤2.5 times UNL ,ALT（SGPT）≤2.5 times UNL,alkaline phosphatase ≤5 times UNL~* FEV1 \>0.8 L~* CB6 within normal limits~* patients and their family signed the informed consents~Exclusion Criteria:~* Previous or recent another malignancy, except nonmelanoma skin cancer or cervical cancer in situ~* Contraindication for chemotherapy~* Malignant pleural or pericardial effusion.~* Women in pregnancy, lactation period, or no pregnancy test 14 days before the first dose~* Women who has the probability of pregnancy without contraception~* Tendency of hemorrhage~* In other clinical trials within 30 days~* Addicted in drugs or alcohol, AIDS patients~* Uncontrollable seizure or psychotic patients without self-control ability~* Severe allergy or idiosyncrasy~* Not suitable for this study judged by researchers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Methylprednisolone (Type: EXPERIMENTAL): Patients were treated with methylprednisolone after the first course of chest radiation and concurrent chemotherapy, once a day, 32 milligram (mg) for 7 days, 24 mg for the next 7 days, then 16mg for 7 days, and 8 mg for the last 7 days.
- Observation (Type: ACTIVE_COMPARATOR): Observation after the first course of chest radiation, methylprednisolone can only be used for therapeutic purpose in the presence of grade≥2 radiation induced lung injury(NCI-CTC4.0).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues